Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

COVID-19 Vaccine Candidates by Identification of B and T Cell Multi-Epitopes Against SARS-COV-2

Suresh Kumar
* ,
Sarmilah Mathavan
,
Wee Jia Jin
,
Nur Azznira Bt Azman
,
Devindren Subramanaiam
,
Nur Afiqah Binti Zainalabidin
,
Dhivashini Lingadaran
,
Zainah Binti Abdul Sattar
,
Danniya Lakshmi Manickam
,
Priscilla Sheba Anbananthan
,
Johan Ahmad Taqiyuddin
,
Yuvapriya Thevarajan
Version 1 : Received: 2 August 2020 / Approved: 4 August 2020 / Online: 4 August 2020 (11:18:27 CEST)

How to cite: Kumar, S.; Mathavan, S.; Jia Jin, W.; Bt Azman, N.A.; Subramanaiam, D.; Binti Zainalabidin, N.A.; Lingadaran, D.; Binti Abdul Sattar, Z.; Manickam, D.L.; Anbananthan, P.S.; Taqiyuddin, J.A.; Thevarajan, Y. COVID-19 Vaccine Candidates by Identification of B and T Cell Multi-Epitopes Against SARS-COV-2. Preprints 2020, 2020080092. https://doi.org/10.20944/preprints202008.0092.v1 Kumar, S.; Mathavan, S.; Jia Jin, W.; Bt Azman, N.A.; Subramanaiam, D.; Binti Zainalabidin, N.A.; Lingadaran, D.; Binti Abdul Sattar, Z.; Manickam, D.L.; Anbananthan, P.S.; Taqiyuddin, J.A.; Thevarajan, Y. COVID-19 Vaccine Candidates by Identification of B and T Cell Multi-Epitopes Against SARS-COV-2. Preprints 2020, 2020080092. https://doi.org/10.20944/preprints202008.0092.v1

Abstract

Coronavirus disease (COVID-19) is a new discovered strain where WHO officially declares the disease as COVID-19 while the virus responsible for it called Severe Acute Respiratory Syndrome Coronavirus 2 or SARS-CoV-2. The incubation period of this disease is between 14 days. Ordinary clinical symptoms that reported around the world include fever, cough, fatigue, diarrhoea and vomiting as well as asymptomatic for certain people. Infection is spread mainly through broad droplets. In early March 2020, WHO again has announced that COVID-19 is a pandemic with currently no specific treatment. The potential use of SARS-COV-2 proteome as a vaccine candidate by analysing through B-cell and T-cell antigenicity by using a immunoinformatics approach as a vaccine development early stage. In this study, we used consensus sequence for SARS-COV-2 proteome that was retrieved from NCBI database. VaxiJen 2.0 was mainly used to identify the antigenic property of SARS-COV-2 proteins. IEDB then used to analyse the B-cell epitope, the presence of T cell immunogenic epitope in SARS-COV-2 proteins was obtained by using compromise method of MHC class I and II tools that accessible respectively using ProPred-1 server and MHC II Binding Prediction in IEDB database. The best epitopes of B and T-cell epitopes were predicted with high antigencity and the information is disseminated through web-based database resource (https://covid-19.omicstutorials.com/epitopes/). This study will be useful to find a new epitope-based candidate for SARS-COV-2. However, further study needs to be done for the next stages of vaccine development.

Keywords

COVID-19; SARS-CoV-2; epitopes; B-cell; T-cell; immuno informatics; MHC-I; MHC-II

Subject

Biology and Life Sciences, Cell and Developmental Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 1
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.